Amazon Secures 200 MW Wind Power Deals in Sweden 
Toyota Global Sales Fall as China Demand Slumps 
France Targets Shein, Temu With Fast-Fashion Fees 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Pinterest Stock Falls as CFO Julia Brau Donnelly Resigns 
CIA-Linked Investor Helped Quantum Systems Expand in US 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Aon Nears $17 Billion Deal to Buy USI Insurance From KKR 
Star Entertainment Shares Fall After A$307 Million FY2026 Loss 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Add as a preferred source on Google
NEW YORK, March 27, 2018 -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will report fourth-quarter and full-year 2017 financial results on Tuesday, April 3, 2018. BeyondSpring’s management team will host a conference call and webcast at 8:00 a.m. Eastern Time on Tuesday, April 3, 2018, to discuss the financial results and provide an operational update.
The conference call may be accessed by dialing (866) 362-6591 (U.S.) or (706) 758-3199 (international) and referencing conference ID 3765248. A live webcast will be available on the Investors page of the Company's website at http://ir.beyondspringpharma.com. An archived replay of the webcast will be available for 30 days.
About BeyondSpring
BeyondSpring is a global, clinical-stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer (Study 103) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN) – (Studies 105 and 106). BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.
Contact:
Investor Relations:
Laura Perry or Joe Rayne
Argot Partners
212.600.1902
[email protected]
